TABLE OF CONTENTS
Volume 86, Issue 3 (September 2009)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use |
Corridendum
In This Issue
In This Issue
In This Issue
Clin Pharmacol Ther 86: 223; doi:10.1038/clpt.2009.156
See also: Macroscopy by Graham et al. See also: State of the Art by Santen et al. See also: State of the Art by Santen et al. See also: Article by Kurata et al. See also: Article by Wajima et al. See also: Article by BergmanEditorial
Drug Development for Emerging Infections
K S Reynolds
Clin Pharmacol Ther 86: 225-229; doi:10.1038/clpt.2009.148
News & Views
Highlights
Highlights
Clin Pharmacol Ther 86: 230-231; doi:10.1038/clpt.2009.158
ASCPT News
ASCPT News
Clin Pharmacol Ther 86: 232-233; doi:10.1038/clpt.2009.153
Macroscopy
Vaccine Development in the Twenty-First Century: Changing Paradigms for Elusive Viruses
B S Graham, J E Ledgerwood and G J Nabel
Clin Pharmacol Ther 86: 234-236; doi:10.1038/clpt.2009.128
Perspectives
Opinion
Evidence-Based Antimicrobial Therapy in Pregnancy: Long Overdue
R N Theiler
Clin Pharmacol Ther 86: 237-238; doi:10.1038/clpt.2009.123
Practice Guidelines: Development, Application to Clinical Care, and Role in Provider Education
J J Kiser
Clin Pharmacol Ther 86: 239-241; doi:10.1038/clpt.2009.143
Stockpiling Antiviral Drugs for the Next Influenza Pandemic
A Patel and S E Gorman
Clin Pharmacol Ther 86: 241-243; doi:10.1038/clpt.2009.142
Commentary
Design, Conduct, and Analysis of Clinical Trials in Disease due to Methicillin-Resistant Staphylococcus aureus
J H Powers and T R Fleming
Clin Pharmacol Ther 86: 244-247; doi:10.1038/clpt.2009.132
State of the Art
State of the Art
From Trial and Error to Trial Simulation. Part 1: The Importance of Model-Based Drug Development for Antidepressant Drugs
G Santen, E van Zwet, M Danhof and O Della Pasqua
Clin Pharmacol Ther 86: 248-254; advance online publication, August 5, 2009; doi:10.1038/clpt.2009.105
See also: State of the Art by Santen et al.From Trial and Error to Trial Simulation. Part 2: An Appraisal of Current Beliefs in the Design and Analysis of Clinical Trials for Antidepressant Drugs
G Santen, J Horrigan, M Danhof and O Della Pasqua
Clin Pharmacol Ther 86: 255-262; advance online publication, August 12, 2009; doi:10.1038/clpt.2009.107
See also: State of the Art by Santen et al.Global Economic and Health Benefits of Tobacco Control: Part 1
H Wipfli and J M Samet
Clin Pharmacol Ther 86: 263-271; advance online publication, June 17, 2009; doi:10.1038/clpt.2009.93
Abstract | Full Text | PDF | Supplementary information
See also: State of the Art by Wipfli & SametGlobal Economic and Health Benefits of Tobacco Control: Part 2
H Wipfli and J M Samet
Clin Pharmacol Ther 86: 272-280; advance online publication, June 17, 2009; doi:10.1038/clpt.2009.94
See also: State of the Art by Wipfli & SametResearch
Reports
Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects
H-D Yoo, S-A Park, H-Y Cho and Y-B Lee
Clin Pharmacol Ther 86: 281-284; advance online publication, June 10, 2009; doi:10.1038/clpt.2009.90
Pretransplant Pharmacodynamic Analysis of Immunosuppressive Agents Using CFSE-Based T-Cell Proliferation Assay
Y Kurata, M Kato, T Kuzuya, Y Miwa, K Iwasaki, M Haneda, K Amioka, Y Watarai, K Uchida, A Nakao and T Kobayashi
Clin Pharmacol Ther 86: 285-289; advance online publication, April 29, 2009; doi:10.1038/clpt.2009.61
Articles
A Comprehensive Model for the Humoral Coagulation Network in Humans
T Wajima, G K Isbister and S B Duffull
Clin Pharmacol Ther 86: 290-298; advance online publication, June 10, 2009; doi:10.1038/clpt.2009.87
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
M V Tzvetkov, S V Vormfelde, D Balen, I Meineke, T Schmidt, D Sehrt, I Saboli
, H Koepsell and J Brockmöller
Clin Pharmacol Ther 86: 299-306; advance online publication, June 17, 2009; doi:10.1038/clpt.2009.92
Heart Failure and Adverse Drug Reactions Among Hospitalized Older Adults
C Catananti, R Liperoti, S Settanni, F Lattanzio, R Bernabei, D Fialova, F Landi and G Onder
Clin Pharmacol Ther 86: 307-310; advance online publication, June 10, 2009; doi:10.1038/clpt.2009.89
Significantly Altered Systemic Exposure to Atorvastatin Acid Following Gastric Bypass Surgery in Morbidly Obese Patients
I B Skottheim, K Stormark, H Christensen, G S Jakobsen, J Hjelmesæth, T Jenssen, J L E Reubsaet, R Sandbu and A Åsberg
Clin Pharmacol Ther 86: 311-318; advance online publication, June 3, 2009; doi:10.1038/clpt.2009.82
UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients
R H N van Schaik, M van Agteren, J W de Fijter, A Hartmann, J Schmidt, K Budde, D Kuypers, Y Le Meur, M van der Werf, R Mamelok and T van Gelder
Clin Pharmacol Ther 86: 319-327; advance online publication, June 3, 2009; doi:10.1038/clpt.2009.83
Discovery & Development
Translational Medicine
The Animal Rule and Emerging Infections: The Role of Clinical Pharmacology in Determining an Effective Dose
K L Bergman
Clin Pharmacol Ther 86: 328-331; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.106
Development
The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development
V Miller
Clin Pharmacol Ther 86: 332-335; advance online publication, July 29, 2009; doi:10.1038/clpt.2009.140
Regulation & Use
Practice
Clinical Challenges in Addressing Resistance to Antimicrobial Drugs in the Twenty-First Century
E J Septimus and K M Kuper
Clin Pharmacol Ther 86: 336-339; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.122
